The past several months have witnessed the emergence of SARS-CoV-2 variants with novel
spike protein mutations that are influencing the epidemiological and clinical aspects of the …

Neutralizing antibodies can block infection, clear pathogens, and are essential to provide
long-term immunity. Since the onset of the pandemic, SARS-CoV-2 neutralizing antibodies …

Continuous evolution of Omicron has led to a rapid and simultaneous emergence of
numerous variants that display growth advantages over BA. 5 (ref.). Despite their divergent …

Background In the phase 1–2 portion of an adaptive trial, REGEN-COV, a combination of the
monoclonal antibodies casirivimab and imdevimab, reduced the viral load and number of …

Background REGEN-COV (previously known as REGN-COV2), a combination of the
monoclonal antibodies casirivimab and imdevimab, has been shown to markedly reduce the …

The recently emerged SARS-CoV-2 Omicron variant encodes 37 amino acid substitutions in
the spike protein, 15 of which are in the receptor-binding domain (RBD), thereby raising …

New variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to
arise and prolong the coronavirus disease 2019 (COVID-19) pandemic. Here, we used a …

Multiple BA. 4 and BA. 5 subvariants with Arg346 mutations in the spike glycoprotein have
been identified in various countries, such as BA. 4.6, BF. 7, BA. 5.2. 6, BA. 4.1. 9, and BE. 1.2 …

The first 2 years of the COVID-19 pandemic were mainly characterized by recurrent
mutations of SARS-CoV-2 Spike protein at residues K417, L452, E484, N501 and P681 …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) initiates the infection
process by binding to the viral cellular receptor angiotensin-converting enzyme 2 through …